Anti-programmed death-1 (PD-1) therapy, as the most representative immunotherapy, acts as an effective cancer therapy through inhibiting local immunosuppression in the tumor microenvironment (TME) and modulating T cell priming against tumor antigens in secondary lymphoid tissues [4]. Here, PDCD1 is linked to neoplasm.